QR Pharma

The economic burden and impact on wellness and quality of life for both patients and their caregivers of Alzheimer’s, Parkinson’s and other neurodegenerative disease is crushing. Today, existing drugs manage the symptoms and provide only marginal cost-benefit trade-offs. Our goal is to develop drugs that stop the progression of these diseases.

QR Pharma’s candidate medicine Posiphen® targets early stage Parkinson’s Disease as well as Alzheimer’s Disease and may stop or slow the progression of those diseases. Posiphen® reduces levels of amyloid precursor protein (APP), tau and α-Synuclein (aSYN), three proteins that can turn toxic and precipitate the onset of neurodegeneration. Posiphen® inhibits APP, tau and aSYN in tissue culture cells, mice as well as in humans. Posiphen® also shows promise in Huntington’s disease, Down Syndrome, Traumatic Brain Injury, and Post Operative Cognitive Decline.